Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.01% is 36% below its 5-year average of 15.77%, near the low end of its 5-year range (5.44%–34.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 18.37% below its 12-month average of 12.26%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.01%.
DEBT TO ASSETS RATIO
10.01%
DEBT TO ASSETS RATIO AVG TTM
12.26%
DEBT TO ASSETS RATIO AVG 3Y
17.42%
DEBT TO ASSETS RATIO AVG 5Y
15.77%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-18.37%
CURRENT VS 3Y AVG
-42.54%
CURRENT VS 5Y AVG
-36.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 530 covered companies
CURRENT VS SECTOR MEDIAN
+9434.76%
vs the sector median at left
IN8bio, Inc.
Market Cap
$13.71M
Debt to Assets Ratio
10.01%
TTM Avg
12.26%
3Y Avg
17.42%
5Y Avg
15.77%
Market Cap
$13.76M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.78M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.44M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.95M
Debt to Assets Ratio
0.69%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.88M
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.23M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.24M
Debt to Assets Ratio
1.94%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.71M | 10.01% | 12.26% | 17.42% | 15.77% |
| Vyome Holdings, Inc. (HIND)vs › | $13.76M | 0.00% | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.78M | 0.04% | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.44M | 0.05% | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.95M | 0.69% | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.88M | 0.30% | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.70M | 0.15% | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.23M | 0.00% | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.24M | 1.94% | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.33M | 0.29% | N/A | N/A | N/A |
Debt/Assets
10.0%
Debt/Equity
0.12
Current Ratio
8.21
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 10.01% |
| 2026-03-31 | 8.96% |
| 2025-12-31 | 8.62% |
| 2025-09-30 | 17.63% |
| 2025-06-30 | 16.10% |
| 2025-03-31 | 21.50% |
| 2024-12-31 | 24.02% |
| 2024-09-30 | 34.27% |
| 2024-06-30 | 26.22% |
| 2024-03-31 | 22.37% |
| 2023-12-31 | 14.52% |
| 2023-09-30 | 20.08% |
| 2023-06-30 | 19.05% |
| 2023-03-31 | 22.40% |
| 2022-12-31 | 17.78% |
| 2022-09-30 | 12.59% |
| 2022-06-30 | 6.48% |
| 2022-03-31 | 6.20% |
| 2021-12-31 | 5.71% |
| 2021-09-30 | 5.44% |
| 2021-06-30 | 11.14% |
| 2021-03-31 | 8.87% |
| 2020-12-31 | 0.83% |
| 2020-06-30 | 4.77% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
